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Abstract 
Purpose: Intravenous (IV) admixtures of diphenhydramine are widely used in hospitalized patients to 
prevent or treat hypersensitivity reactions. However, there is limited data to support the admixture 
preparation in this manner. This study was designed to investigate the stability and compatibility of 
diphenhydramine in IV admixtures with a goal to establish a 14-day beyond-use dating with storage under 
refrigeration. Methods: The commercially available 50 mg/mL diphenhydramine hydrochloride injection 
vials were used to prepare the 0.2 and 1.0 mg/mL IV admixtures in 0.9% sodium chloride injection and 5% 
dextrose injection in 50 mL polyvinyl chloride (PVC) bags. The IV bags were sealed and stored under 
refrigeration (2°C-8°C) for the stability study. At each predetermined time point, samples were taken for 
visual inspection, pH measurement, and analysis by a stability-indicating high-performance liquid 
chromatography (HPLC) method. Results: The freshly prepared IV admixtures appeared clear, colorless, 
and particulate-free with pH readings of 4.44 to 4.60. The initial drug concentrations of all samples were 
confirmed by HPLC to be within 101.8% to 103.6% of the label claims. Over the 14 days of the study 
period, there was no significant change in the appearance or pH values for all stability samples. The HPLC 
results also confirmed that there was no more than ±2% change of the initial drug concentration in any 
stability samples. Conclusion: Diphenhydramine hydrochloride IV admixtures of 0.2 and 1.0 mg/mL are 
compatible with 0.9% sodium chloride injection and 5% dextrose injection in PVC bags. These IV 
admixtures are stable chemically and physically for up to 14 days when stored under refrigeration 
(2°C-8°C). 
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Abstract: 
Purpose: Intravenous (IV) admixtures of diphenhydramine are widely used in hospitalized patients 
to prevent or treat hypersensitivity reactions. However, there is limited data to support the 
admixture preparation in this manner. This study was designed to investigate the stability and 
compatibility of diphenhydramine in IV admixtures with a goal to establish a 14-day beyond-use 
dating with storage under refrigeration. 
Methods: The commercially available 50 mg/mL diphenhydramine hydrochloride injection vials 
were used to prepare the 0.2 and 1.0 mg/mL IV admixtures in 0.9% sodium chloride injection and 
5% dextrose injection in 50 mL polyvinyl chloride (PVC) bags. The IV bags were sealed and stored 
under refrigeration (2 - 8°C) for the stability study. At each pre-determined time point, samples were 
taken for visual inspection, pH measurement, and analysis by a stability-indicating high performance 
liquid chromatography (HPLC) method. 
Results: The freshly prepared IV admixtures appeared clear, colorless, and particulate-free with pH 
readings of 4.44 – 4.60. The initial drug concentrations of all samples were confirmed by HPLC to 
be within 101.8 – 103.6% of the label claims. Over the 14 days of the study period, there was no 
significant change in the appearance or pH values for all stability samples. The HPLC results also 
confirmed that there was no more than ±2% change of the initial drug concentration in any stability 
samples.  
Conclusion: Diphenhydramine hydrochloride IV admixtures of 0.2 and 1.0 mg/mL are compatible 
with 0.9% sodium chloride injection and 5% dextrose injection in PVC bags. These IV admixtures 
are stable chemically and physically for up to 14 days when stored under refrigeration (2 - 8°C). 
Key Words: Benadryl, diphenhydramine, anaphylaxis, compounding, stability, compatibility, IV, 
admixture   
 Introduction: 
Diphenhydramine, a first-generation H1 antihistamine introduced back in 1946,
1-2 has been 
used to treat a variety of conditions, such as allergies, insomnia, motion sickness, and parkinsonism.3 
Currently, systemic diphenhydramine is widely used in therapies as an adjunctive agent to prevent or 
treat hypersensitivity reactions caused by many agents.4 In particular, many published studies have 
used either oral or intravenous (IV) diphenhydramine as part of a premedication series before 
administering chemotherapy or immunotherapy treatments.5 
The IV administration of diphenhydramine provides rapid achievement of therapeutic 
effects and bypasses potential absorption issues. It is an attractive choice for some therapies and can 
be administered via IV push or IV infusion. While IV push of diphenhydramine would yield a fast 
onset, it may lead to potential side effects and thus requires additional nursing time to monitor 
patients. IV infusion of diphenhydramine, as diluted IV admixtures, allows the medication to be 
safely administered to patients.3,6 
Even though the IV infusion therapy of diphenhydramine is widely used, there is limited 
information from the manufacturers or published literature to support the stability and compatibility 
of diphenhydramine IV admixtures at commonly used dosages.7-9 A typical dose of 25 to 50 mg of 
diphenhydramine hydrochloride (HCl) prepared in a commercially available 50 or 100 mL IV bag 
would result in a theoretical concentration range of 0.25 to 1.0 mg/mL. The actual concentrations 
would be slightly lower due to bag overfill and additive volume. The purpose of this study was to 
evaluate the stability and compatibility of 0.2 and 1.0 mg/mL diphenhydramine HCl admixtures in 
0.9% sodium chloride injection and 5% dextrose injection in polyvinyl chloride (PVC) IV bags 
stored under refrigeration (2 - 8°C) for up to 14 days. 
  
 Methods: 
Materials for IV Admixtures 
 Diphenhydramine HCl Injection, USP, 50 mg/mL, 1-mL vials, were purchased from 
Fresenius Kabi (NDC#63323-664-16; lot# 6011913). The diluents used to prepare the IV 
admixtures were obtained from 250 mL bags of 0.9% Sodium Chloride Injection, USP from Baxter 
(NDC#0338-0049-02, lot# Y234302) and 5% Dextrose Injection, USP from Baxter (NDC#0338-
0017-02, lot# Y228320). Sterile empty 50 mL IV bags were not available commercially at the time of 
the study. Therefore, 50 mL bags of 0.9% Sodium Chloride Injection, USP (NDC#0338-0049-31, 
lot# P360990) and 5% Dextrose Injection, USP (NDC#0338-0017-11, lot# P349647) were 
purchased from Baxter. The fluid in each 50 mL bag was completely removed under aseptic 
conditions prior to packaging of the stability samples. The material of these bags was polyvinyl 
chloride (PVC).  
 
Materials for High Performance Liquid Chromatography (HPLC) Analysis 
 A Milli-Q Direct 8 system from Millipore Sigma (Burlington, MA) was used to produce Type 
I (ultrapure) water. Acetonitrile and trifluoroacetic acid, both HPLC grades, were purchased from 
Thermo Fisher Scientific (Waltham, MA). Diphenhydramine HCl powder (99% purity) was 
purchased from Acros Organics (Cat# AC350850250, lot# A0370928) and used as a reference 
standard for HPLC calibration purpose. 
 
pH Analysis 
 A Mettler-Toledo SevenEasy model pH meter (Columbus, OH) was used with a gel-filled 
pencil-thin pH electrode from Fisher Scientific (Cat# 13-620-290). The pH meter was calibrated 
daily with standard pH 4 and 7 buffer solutions purchased from Fisher Scientific (Cat# SB101-500 
 and SB107-500). 
 
HPLC Analysis 
 A reversed-phase HPLC method was developed for diphenhydramine to measure drug 
concentration and monitor drug stability. A Model LC-2010A system from Shimadzu Scientific 
Instruments (Marlborough, MA) was equipped with a C18, 3 µm, 100 A, 4.6×150 mm column from 
Phenomenex (Torrance, CA) as the stationary phase. The mobile phase consisted of 
water:acetonitrile (63:37) with 0.1% trifluoroacetic acid, and the pH was approximately 2.0. 
Additional instrument parameters were set as follows: column temperature at 40°C, mobile phase 
flow rate of 0.6 mL/min, sample injection volume of 5 µL, and UV detection at 220 nm. Data 
collection and processing was performed by the Shimadzu LC Solution software.  
 For calibration purpose, five standard solutions of diphenhydramine HCl (0.16, 0.18, 0.20, 
0.22, and 0.24 mg/mL) were run on each analysis day. This range encompasses the 80 – 120% of the 
expected concentration of the HPLC samples. These standards were prepared from the pure 
diphenhydramine HCl powder dissolved in water. A calibration curve was constructed on each 
analysis day by plotting the peak area against concentration. The mid-point standard of 0.20 mg/mL 
was also injected 3 times on each analysis day to monitor the intra-day and inter-day variability of the 
HPLC method. 
 
Forced Degradation Study 
 A forced degradation study was performed to confirm that the above HPLC method could 
separate the potential degradation products from the original drug. As listed in Table 1, four drug 
samples of 0.20 mg/mL were subjected to different stress conditions of extreme pH, oxidizing 
agent, heat, and light. Samples #1 and #2 were adjusted to pH 2 and pH 12 by adding 1 M 
 hydrochloric acid and 1 M sodium hydroxide, respectively. Samples #3 and #4 were both spiked 
with concentrated hydrogen peroxide to a final concentration of 3%. Samples #1, 2, and 3 were 
incubated at 60°C, and Sample #4 was exposed to direct sunlight at ambient room temperature. All 
four samples were monitored by the HPLC analysis until a minimum of 10% degradation was 
observed in at least one of the four samples.10-11  
  
14-Day Stability Study of IV Admixtures 
Four IV admixtures of diphenhydramine were prepared for this stability study which 
included two drug concentrations (0.2 and 1.0 mg/mL) and two diluents (0.9% sodium chloride 
injection and 5% dextrose injection). To ensure accurate initial drug concentrations and avoid issues 
due to variable bag overfill volumes, the admixtures were prepared in clean beakers using 
appropriate measuring devices. To prepare each batch of 0.2 mg/mL diphenhydramine HCl 
admixture, 0.8 mL of the 50 mg/mL drug solution was mixed with 199.2 mL diluent. To prepare 
each batch of 1.0 mg/mL diphenhydramine HCl admixture, 4.0 mL of the 50 mg/mL drug solution 
was mixed with 196.0 mL diluent. Both drug and diluent solutions were aqueous, so the volumes 
were assumed to be additive and the final volume of each batch was 200 mL. Each admixture batch 
was filled into 3 replicate bags, 50 mL per bag. Please note that each batch included an overage of 50 
mL to account for potential losses due to transfer or void space. The IV bag samples were sealed, 
labeled, and placed on stability study in a refrigerator (2 – 8°C). All preparation steps described 
above were carried out under aseptic conditions to minimize contamination.  
The predefined study time points for this study were 0, 1, 3, 7, and 14 days. At each study 
time point, the admixture bags were first visually inspected for color, clarity, and particulate matters. 
For the HPLC analysis and pH measurement, a 1 mL aliquot was aseptically withdrawn from each 
admixture bag and placed into a microcentrifuge tube. For the 0.2 mg/mL stability samples, 100 µL 
 was transferred from the microcentrifuge into HPCL vials with inserts for direct HPLC analysis. For 
the 1.0 mg/mL stability samples, 100 µL was transferred into regular HPLC vials and diluted to 0.2 
mg/mL with 400 µL water prior to HPLC analysis. The remaining 900 µL stability sample in each 
microcentrifuge tube was used directly for pH measurement. 
 
  
 Results and Discussion: 
General Considerations 
Diphenhydramine is available commercially as a variety of dosage forms2,3 prepared from 
either the hydrochloride (HCl) and citrate salt forms.7,12 All product strengths are labeled based on 
the salt form (not the free base).7,12 The only parenteral product available is a 50 mg/mL 
diphenhydramine HCl solution packaged in 1-mL vials or prefilled syringes.2,3,7 Accordingly to the 
package inserts,7 the solution is adjusted to pH 4.5 – 6.0 with either sodium hydroxide or 
hydrochloric acid and contains no other excipients. This 50 mg/mL parenteral solution is 
considered the most suitable drug source to prepare any desired IV admixtures because of its sterile 
product quality and simple formulation. Although the USP grade of diphenhydramine HCl powder 
is available commercially and can technically be used to prepare IV admixtures followed by 
sterilization, the resulting preparations would be considered high-risk for potential microbial 
contamination.13 
Diphenhydramine is a small organic molecule with the chemical structure shown in Figure 1 
as the HCl salt.7 The main stability concerns are the potential hydrolysis of the ether group and 
oxidation of the ether and aromatic groups. The drug has an ionizable tertiary amine group with a 
pKa ~ 9.
14 The HCl salt is freely soluble in water (100 – 1000 g/mL),7,14 so there are minimal 
concerns for precipitation at the desired concentration range of 0.2 – 1.0 mg/mL for IV admixtures. 
However, drug loss due to sorption to plastic IV bag materials may become problematic for dilute 
drug solutions. 
 
HPLC Method and Forced Degradation Study 
With the HPLC method conditions described in the Methods section, diphenhydramine 
exhibited a consistent retention time of 6.4 – 6.5 minutes. A representative chromatogram is shown 
 in Figure 1. The calibration curves were found to be linear over the concentration range of the 
standards (0.16 – 0.24 mg/mL) with R2 = 0.989 or better. The intra-day coefficient of variation (CV) 
was within 0.162%, and the inter-day CV over the study period was within 0.534%. 
 The results of the forced degradation study are summarized in Table 1. Significant drug 
degradation (>80%) was observed in the samples spiked with 3% H2O2 within 24 hours. Moderate 
amount of degradation (<20%) also occurred in samples exposed to extreme pH. In all samples, the 
degradation product peaks were well separated from the original drug peak. Therefore, this HPLC 
method was considered stability-indicating and suitable for the planned 14-day stability study of the 
IV admixtures. 
 
14-Day Stability Study of IV Admixtures 
Four diphenhydramine HCl IV admixtures were evaluated for the 14-day stability study. 
These admixtures included two drug concentration levels of 0.2 and 1.0 mg/mL in two commonly 
used IV vehicles of 0.9% sodium chloride and 5% dextrose. At the initiation of the stability study, all 
IV bags appeared as clear and colorless solutions with no visible particulate matters. The pH and 
HPLC results are presented in Table 2 and Table 3. The initial pH readings of the four admixtures 
ranged from 4.44-4.60, and these values were consistent to the pH range of the source drug solution 
(4.5-6.0)7,12 and vehicles (4.5-7.0 for sodium chloride injection and 3.2-6.5 for dextrose injection)15,16. 
The initial drug concentrations of the four admixtures matched closely to the expected values, 
representing 101.8 – 103.6% of the label claims.  
Over 14 days of storage under refrigeration, all stability samples remained clear, colorless, 
and free of visible particulates. As shown in Table 2, a small drift of 0.55 pH unit was observed for 
the 0.2 mg/mL admixture in 5% dextrose, and no significant changes in pH were observed for the 
other three admixtures. As shown in Table 3, the HPLC data suggested that all admixtures retained 
 98.6 – 100.8 % of their initial drug concentrations. In addition, all the HPLC chromatograms were 
examined carefully for potential degradation products or leachables from packaging, and no new 
peaks were observed in any samples.  
Overall, the study results suggested that 0.2 – 1.0 mg/mL diphenhydramine hydrochloride 
IV admixtures are compatible in 0.9% sodium chloride injection and 5% dextrose injection in PVC 
bags. These IV admixtures are stable chemically and physically for up to 14 days under refrigeration. 
The authors would like to point out that the diphenhydramine admixtures were batched in 
beakers prior to packaging into IV bags in this study. This approach was used in order to achieve the 
accurate and consistent starting drug concentrations in the IV bags. The actual IV admixtures for 
patient use should be prepared as individual doses directly in the IV bags, following all pertinent 
requirements in USP general chapter 797 for sterile compounding.13 It is also advised to verify the 
overfill volume of IV bags to ensure that the final drug concentration in the admixture is within the 
0.2 – 1.0 mg/mL range covered in this study. 
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 Figure 1. A representative HPLC chromatogram of 0.2 mg/ml diphenhydramine HCl standard 
solution and the chemical structure of diphenhydramine HCl  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Forced Degradation Study of Diphenhydramine HCl 
Sample # Stress Conditions 
% Drug Remaining  
after 24 Hours 
1 pH 2 and 60°C 82.3% 
2 pH 12 and 60°C 94.8% 
3 3% H2O2 and 60°C 6.6% 
4 3% H2O2 and sun light 18.9% 
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 Table 2. pH Results of the 14-Day Diphenhydramine HCl Admixture Stability Study (n = 3) 
Sample 
pH 
Day 0 Day 1 Day 3 Day 7 Day 14 
0.2 mg/mL  
in 0.9% Sodium 
Chloride Injection 
4.57 ± 0.05 4.57 ± 0.04 4.61 ± 0.03 4.57 ± 0.04 4.60 ± 0.01 
1.0 mg/mL  
in 0.9% Sodium 
Chloride Injection 
4.60 ± 0.09 4.65 ± 0.12 4.62 ± 0.05 4.61 ± 0.06 4.60 ± 0.05 
0.2 mg/mL  
in 5% Dextrose 
Injection 
4.44 ± 0.02 4.46 ± 0.09 4.61 ± 0.11 4.84 ± 0.12 4.99 ± 0.06 
1.0 mg/mL  
in 5% Dextrose 
Injection 
4.60 ± 0.04 4.65 ± 0.04 4.87 ± 0.06 4.66 ± 0.04 4.69 ± 0.04 
 
Table 3. HPLC Results of the 14-Day Diphenhydramine HCl Admixture Stability Study (n = 3) 
Sample 
Initial Drug 
Concentration 
(mg/mL) 
% Initial Concentration Remaining 
Day 1 Day 3 Day 7 Day 14 
0.2 mg/mL  
in 0.9% Sodium 
Chloride Injection 
0.2052 ± 0.0004 100.6 ± 0.4 100.0 ± 0.4 100.8 ± 0.5 100.6 ± 0.4 
1.0 mg/mL  
in 0.9% Sodium 
Chloride Injection 
1.035 ± 0.007 100.5 ± 0.6 100.2 ± 0.6 100.5 ± 0.2 99.5 ± 1.5 
0.2 mg/mL  
in 5% Dextrose 
Injection 
0.2037 ± 0.0001 100.6 ± 0.3 100.4 ± 0.2 101.1 ± 0.3 100.8 ± 0.3 
1.0 mg/mL  
in 5% Dextrose 
Injection 
1.036 ± 0.006 98.6 ± 1.8 100.5 ± 0.2 99.5 ± 0.2 99.3 ± 0.6 
 
